For FQHCs and other 340B covered entities, 2027 is unlikely to be a year of business as usual. The program is moving toward more claims-level data, more formal reporting, closer manufacturer scrutiny, and greater pressure on executives to explain how 340B operations affect finances, compliance, and patient access.

The following predictions are an outlook: not a statement that every development is final. Each point separates what is confirmed, what is proposed, and what is reasonably expected based on current federal activity and industry direction.

Board-Ready Summary

2027 prediction	Current status	Primary exposure	Board-level preparation
The 340B rebate model expands or matures	Expected; initial manufacturer approvals are expected by September 24, 2026	WAC cash exposure, delayed rebates, claims denials	Model cash flow and test rebate workflows
CMS data submission becomes a real compliance burden	2026 repository launch established; 2027 mandate proposed	Incomplete files, missed deadlines, Medicare enrollment risk if finalized	Establish quarterly data governance
Manufacturer ESP and contract pharmacy rules keep shifting	Expected based on ongoing policy changes	Pricing restrictions, submission failures, pharmacy disruption	Maintain a manufacturer and state policy matrix
Legislative pressure builds	SECURE and SUSTAIN proposals are not enacted	New reporting, attestation, patient, and contract pharmacy controls	Prepare for claims-level transparency
Data-governed entities pull ahead	Strategic expectation	Missed savings, weak oversight, poor decision-making	Build consolidated dashboards and accountability

Prediction 1: The 340B Rebate Model Will Expand or Mature

Status: Expected, not guaranteed.

The HRSA 340B Rebate Model Pilot is expected to reach an important milestone in late 2026. Manufacturer plan approvals are expected by September 24, 2026, with the earliest effective date of January 1, 2027. The initial model is limited to selected drugs associated with the Medicare Drug Price Negotiation Program, but additional manufacturers or drugs may follow if the pilot becomes operationally viable.[^1]

The model changes the timing of the benefit. Instead of receiving the 340B discount at purchase, a covered entity may purchase at wholesale acquisition cost, submit claims-level information after dispensing, and receive a rebate intended to bring the net cost down to the 340B ceiling price.

For your CFO, this creates a working-capital issue. For your 340B director, it creates a new operational workflow:

BUY → DISPENSE → SUBMIT → VALIDATE → RECEIVE → RECONCILE

Your preparation should include:

Identify drugs and manufacturers likely to fall within approved plans.
Model WAC purchases, expected rebate amounts, and payment timing.
Confirm your systems capture NDC, quantity, date of dispense, payer, and 340B identifiers.
Track claims submitted, paid, denied, and awaiting resolution.
Reconcile rebate receipts to pharmacy, wholesaler, TPA, and general ledger records.

Review GapRx’s guide to how the 340B rebate model works, rebate model timeline, and CFO decision framework before finalizing your 2027 budget.

340B compliance professionals reviewing pharmacy and regulatory documentation

Prediction 2: CMS Data Submission Will Become a Real Compliance Burden

Status: 2026 repository launch established; 2027 mandate proposed, not final.

CMS has scheduled the Medicare Part D 340B claims data repository to open for voluntary submissions on October 1, 2026. CMS has also proposed requiring applicable 340B Medicare providers and suppliers to submit data beginning with claims dated January 1, 2027. Under the proposal, reporting could become a condition of continued Medicare enrollment.[^2]

That proposal may change before a final rule is issued. However, waiting for certainty could create a preventable data crisis.

The operational nightmare is not the portal itself. It is assembling complete, accurate information across:

In-house pharmacies.
Contract pharmacies.
TPAs.
Pharmacy benefit systems.
NDC and NPI files.
Covered entity and child-site records.
Reversals, corrections, and exception files.

Your entity should treat this as a data-governance project. Assign an executive owner, document TPA delegation, establish quarterly deadlines, and retain submission confirmations and correction records.

At minimum, test your ability to produce the required claim-level fields, including the covered entity 340B ID, date of service, prescription or service reference number, fill number, NDC-11, and dispensing pharmacy NPI.

Read the CMS Medicare Part D 340B Repository overview and build your 2027 calendar before the first reporting deadline arrives.

Prediction 3: Manufacturer ESP and Contract Pharmacy Policies Will Keep Shifting

Status: Expected.

Manufacturer contract pharmacy policies, claims-data requirements, state carve-outs, and pricing access conditions continue to evolve. More manufacturers are expected to tighten validation requirements, limit designated pharmacies, require ESP submissions, or scrutinize the relationship between contract pharmacy claims and wholesaler chargebacks.

The risk for FQHCs is operational fragmentation. One manufacturer may require a different submission process, timing window, pharmacy designation, or exception workflow than another.

For 340B directors, the practical response is a current manufacturer policy matrix that tracks:

Affected products.
Contract pharmacy limitations.
ESP or other data submission requirements.
State-specific exceptions.
Submission deadlines.
Required identifiers.
Open denials and pricing access issues.
Responsible internal and external owners.

Do not assume your TPA is managing this risk completely. Your entity remains responsible for oversight, documentation, escalation, and program performance.

GapRx’s manufacturer compliance and 340B ESP support can help organize claims-level validation, submission tracking, manufacturer notice review, and exception management. Also review 7 mistakes in 340B ESP management to identify gaps in your current process.

Tablet displaying a 340B claims management dashboard

Prediction 4: Legislative Pressure Will Build Around Transparency and MFP Coordination

Status: Proposed legislation; future effects remain uncertain.

The House SECURE 340B Act and the Senate SUSTAIN 340B Act represent competing approaches to 340B reform. Neither proposal should be treated as enacted law. However, both signal the direction of the debate: more claims-level data, clearer patient and contract pharmacy standards, stronger transparency, and greater program oversight.[^3]

The proposals differ on rebate models, clearinghouse design, reporting requirements, and implementation timelines. Yet the strategic message is similar: covered entities should expect more scrutiny of how 340B claims are identified, documented, and reconciled.

MFP coordination adds another layer. Public proposals and current federal pricing programs do not establish a single, final MFP-340B operating model for every entity. Still, claims-level data will likely become increasingly important for preventing duplicate discounts and demonstrating how different federal pricing mechanisms interact.

Your preparation should include:

Review patient eligibility and encounter documentation.
Maintain accurate child-site and provider records.
Formalize contract pharmacy agreements and oversight.
Document Medicaid carve-in and carve-out decisions.
Prepare for possible attestations or executive certifications.
Maintain a defensible audit trail from prescription to purchase and payment.

For context, compare the SECURE 340B Act with current analysis of the SECURE and SUSTAIN legislative proposals.

Prediction 5: Data-Governed Entities Will Pull Ahead

Status: Strategic expectation.

In 2027, analytics will move from a reporting convenience to a competitive advantage. Covered entities that can see their claims, savings, capture rates, denials, vendor performance, and compliance exceptions in one place will make faster decisions than entities managing the program through disconnected spreadsheets and portals.

A strong data-governance model should answer five questions:

Completeness: Did we receive all expected files?
Accuracy: Are NDCs, NPIs, dates, quantities, and 340B IDs correct?
Timeliness: Were submissions made within the required window?
Reconciliation: Do claims, purchases, rebates, and financial records agree?
Accountability: Who owns each exception and corrective action?

Your dashboard should monitor:

Capture rate by pharmacy, site, provider, and payer.
Gross and net savings.
In-house versus contract pharmacy performance.
Missing files, duplicates, reversals, and unmatched claims.
ESP and CMS submission status.
Rebate aging and denial reasons.
Manufacturer restriction impact.
Open audit and corrective-action items.

GapRx’s 340B analytics and program dashboards help covered entities consolidate data from pharmacies, TPAs, wholesalers, claims vendors, and finance systems into actionable views for leadership and operations.

Your 2027 Planning Checklist

Before the new year, your executive team should be able to answer:

Which rebate-model drugs could affect our cash flow?
Can we produce complete CMS repository data if the proposed mandate is finalized?
Which manufacturers currently restrict our contract pharmacy relationships?
Are our ESP submissions timely, accurate, and documented?
Can we reconcile claims, purchases, rebates, and general ledger activity?
Which dashboard metrics will the board review each quarter?
Who owns each operational and compliance exception?

The central lesson is straightforward: 340B risk is becoming a data problem, a financial problem, and a governance problem at the same time.

Covered entities that prepare early will be better positioned to protect savings, preserve pharmacy access, respond to audits, and support patient services. Entities that wait for every rule to become final may discover that the implementation deadline arrives before their data, vendors, and internal controls are ready.

For help assessing your organization’s rebate readiness, manufacturer compliance, contract pharmacy oversight, or analytics environment, schedule a 340B strategy call with GapRx.

Sources

[^1]: HRSA, Notice Regarding the 340B Rebate Model Pilot Program
[^2]: CMS, Medicare Part D 340B Repository FAQs
[^3]: Congress.gov, SECURE 340B Act

2027 340B Outlook: 5 Predictions Every Covered Entity Should Plan Around